The Changing Paradigms for Breast Cancer Surgery

Performing Fewer and Less-Invasive Operations

David W. Ollila, E. Shelley Hwang, David R. Brenin, Henry M. Kuerer, Katharine Yao, Sheldon M. Feldman

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Historically, through the conduct of prospective clinical trials, breast cancer surgeons have performed less radical breast and axillary surgeries with no survival decrement to our patients. Currently, other opportunities exist for the treating breast surgeon to do less. Possibilities include active surveillance for ductal carcinoma in situ, ablative therapy for small primary breast cancers, selective omission of a sentinel node biopsy, and selective elimination of breast surgery after neoadjuvant systemic therapy. Breast surgeons must be leaders in the development and testing of effective therapy with the least intervention possible.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalAnnals of Surgical Oncology
DOIs
StateAccepted/In press - Jul 2 2018

Fingerprint

Breast
Breast Neoplasms
Carcinoma, Intraductal, Noninfiltrating
Neoadjuvant Therapy
Clinical Trials
Biopsy
Survival
Therapeutics
Surgeons

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

The Changing Paradigms for Breast Cancer Surgery : Performing Fewer and Less-Invasive Operations. / Ollila, David W.; Hwang, E. Shelley; Brenin, David R.; Kuerer, Henry M.; Yao, Katharine; Feldman, Sheldon M.

In: Annals of Surgical Oncology, 02.07.2018, p. 1-6.

Research output: Contribution to journalArticle

Ollila, David W. ; Hwang, E. Shelley ; Brenin, David R. ; Kuerer, Henry M. ; Yao, Katharine ; Feldman, Sheldon M. / The Changing Paradigms for Breast Cancer Surgery : Performing Fewer and Less-Invasive Operations. In: Annals of Surgical Oncology. 2018 ; pp. 1-6.
@article{d216c3df83cb40aba14b5eb5b7f86d0d,
title = "The Changing Paradigms for Breast Cancer Surgery: Performing Fewer and Less-Invasive Operations",
abstract = "Historically, through the conduct of prospective clinical trials, breast cancer surgeons have performed less radical breast and axillary surgeries with no survival decrement to our patients. Currently, other opportunities exist for the treating breast surgeon to do less. Possibilities include active surveillance for ductal carcinoma in situ, ablative therapy for small primary breast cancers, selective omission of a sentinel node biopsy, and selective elimination of breast surgery after neoadjuvant systemic therapy. Breast surgeons must be leaders in the development and testing of effective therapy with the least intervention possible.",
author = "Ollila, {David W.} and Hwang, {E. Shelley} and Brenin, {David R.} and Kuerer, {Henry M.} and Katharine Yao and Feldman, {Sheldon M.}",
year = "2018",
month = "7",
day = "2",
doi = "10.1245/s10434-018-6618-z",
language = "English (US)",
pages = "1--6",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",

}

TY - JOUR

T1 - The Changing Paradigms for Breast Cancer Surgery

T2 - Performing Fewer and Less-Invasive Operations

AU - Ollila, David W.

AU - Hwang, E. Shelley

AU - Brenin, David R.

AU - Kuerer, Henry M.

AU - Yao, Katharine

AU - Feldman, Sheldon M.

PY - 2018/7/2

Y1 - 2018/7/2

N2 - Historically, through the conduct of prospective clinical trials, breast cancer surgeons have performed less radical breast and axillary surgeries with no survival decrement to our patients. Currently, other opportunities exist for the treating breast surgeon to do less. Possibilities include active surveillance for ductal carcinoma in situ, ablative therapy for small primary breast cancers, selective omission of a sentinel node biopsy, and selective elimination of breast surgery after neoadjuvant systemic therapy. Breast surgeons must be leaders in the development and testing of effective therapy with the least intervention possible.

AB - Historically, through the conduct of prospective clinical trials, breast cancer surgeons have performed less radical breast and axillary surgeries with no survival decrement to our patients. Currently, other opportunities exist for the treating breast surgeon to do less. Possibilities include active surveillance for ductal carcinoma in situ, ablative therapy for small primary breast cancers, selective omission of a sentinel node biopsy, and selective elimination of breast surgery after neoadjuvant systemic therapy. Breast surgeons must be leaders in the development and testing of effective therapy with the least intervention possible.

UR - http://www.scopus.com/inward/record.url?scp=85049584209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049584209&partnerID=8YFLogxK

U2 - 10.1245/s10434-018-6618-z

DO - 10.1245/s10434-018-6618-z

M3 - Article

SP - 1

EP - 6

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

ER -